Another Elagolix Study Supports AbbVie's NDA, But Which Dose?
This article was originally published in Scrip
Executive Summary
A second positive Phase III clinical trial for AbbVie Inc.'s elagolix in the treatment of endometriosis pain in premenopausal women supports a new drug application (NDA) submission to the US FDA in 2017, but it's unknown whether both doses tested in the trials will be viable in the real world.
You may also be interested in...
Keeping Track: Thumbs Up For Abbvie and GSK; Thumbs Down For Insys
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review
The latest drug development news and highlights from our US FDA Performance Tracker.